SC 13G/A: Merck & Co., Inc.
Ticker: MRK · Form: SC 13G/A · Filed: 2024-11-06T00:00:00.000Z
Sentiment: neutral
Topics: sc-13g-a
AI Summary
SC 13G/A filing by Merck & Co., Inc..
Risk Assessment
Risk Level: low
From the Filing
0000895345-24-000536.txt : 20241106 0000895345-24-000536.hdr.sgml : 20241106 20241106160957 ACCESSION NUMBER: 0000895345-24-000536 CONFORMED SUBMISSION TYPE: SC 13G/A PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20241106 DATE AS OF CHANGE: 20241106 SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: Evaxion Biotech A/S CENTRAL INDEX KEY: 0001828253 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: G7 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13G/A SEC ACT: 1934 Act SEC FILE NUMBER: 005-94294 FILM NUMBER: 241430995 BUSINESS ADDRESS: STREET 1: DR NEERGAARDS VEJ 5F CITY: HOERSHOLM STATE: G7 ZIP: 2970 BUSINESS PHONE: 004531262615 MAIL ADDRESS: STREET 1: DR NEERGAARDS VEJ 5F CITY: HOERSHOLM STATE: G7 ZIP: 2970 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: Merck & Co., Inc. CENTRAL INDEX KEY: 0000310158 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 221918501 STATE OF INCORPORATION: NJ FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13G/A BUSINESS ADDRESS: STREET 1: 2000 GALLOPING HILL ROAD CITY: KENILWORTH STATE: NJ ZIP: 07033 BUSINESS PHONE: 908-740-4000 MAIL ADDRESS: STREET 1: 2000 GALLOPING HILL ROAD CITY: KENILWORTH STATE: NJ ZIP: 07033 FORMER COMPANY: FORMER CONFORMED NAME: Merck & Co. Inc. DATE OF NAME CHANGE: 20091103 FORMER COMPANY: FORMER CONFORMED NAME: SCHERING PLOUGH CORP DATE OF NAME CHANGE: 19920703 SC 13G/A 1 ff4087100_13ga1-evaxion.htm     UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549   SCHEDULE 13G   Under the Securities Exchange Act of 1934 (Amendment No. 1)*   Evaxion Biotech A/S (Name of Issuer)   Ordinary Shares, DKK 1 nominal value per share (Title of Class of Securities)   29970R204** (CUSIP Number)   September 30, 2024 (Date of Event Which Requires Filing of this Statement)   Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☐ Rule 13d-1(b)     ☒ Rule 13d-1(c)     ☐ Rule 13d-1(d)   * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.   ** This CUSIP number applies to the American Depositary Shares, each representing ten Ordinary Shares, DKK 1 nominal value per share. No CUSIP number has been assigned to the Ordinary Shares.   The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).     CUSIP No. 29970R204 13G/A Page 2 of 8 Pages 1 NAMES OF REPORTING PERSONS       Merck & Co., Inc.         2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP     (a) ☐     (b) ☐     3 SEC USE ONLY               4 CITIZENSHIP OR PLACE OF ORGANIZATION       New Jersey         NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH 5 SOLE VOTING POWER       0         6 SHARED VOTING POWER       7,720,588 (1)         7 SOLE DISPOSITIVE POWER       0         8 SHARED DISPOSITIVE POWER       7,720,588 (1)         9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON       7,720,588 (1)         10 CHECK IF THE AGGREGATE